Wearable Devices Track Menopause While Weight-Loss Drugs Surge in Young Patients Despite Low Overall Uptake
Wearable technology such as smartwatches can help track various symptoms and health indicators during menopause, offering new monitoring possibilities for women managing this transition. Prescription rates for GLP-1 medications among adolescents eligible for bariatric surgery increased dramatically between 2017 and 2025, though the vast majority of eligible teens remain untreated. Research also confirms that iatrogenic menopause induced by medical treatments significantly elevates cardiovascular risks including stroke and heart disease.
Wearable technology is emerging as a practical tool for women navigating menopause, enabling real-time monitoring of symptoms and physiological changes through devices already in widespread use. This development offers a less invasive alternative to traditional clinical monitoring approaches.
The use of GLP-1 medications among adolescents has grown substantially over the past decade, particularly among those who would qualify for weight-loss surgery. However, this expansion remains limited relative to the total population of eligible teenagers, suggesting significant barriers to treatment access or awareness persist in this age group.
These developments could reshape how healthcare providers approach weight management and hormonal transitions in younger populations. Broader access to GLP-1 treatments might improve outcomes for adolescents with severe obesity, while wearable monitoring could empower women to manage menopause symptoms more proactively. However, such trends may also raise questions about medication costs, long-term safety profiles in younger patients, and whether technological solutions adequately address underlying health inequities in treatment availability.